Research & Literature

The Role of ExoS in Dissemination of Pseudomonas aeruginosa during Pneumonia.

Rangel SM, Diaz MH, Knoten CA, et al.

PLoS pathogens 2015; (11(6)):e1004945 doi:10.1371/journal.ppat.1004945.

PslG, a self-produced glycosyl hydrolase, triggers biofilm disassembly by disrupting exopolysaccharide matrix.

Yu S, Su T, Wu H, et al.

Cell research 2015; (25(12)):1352-67 doi:10.1038/cr.2015.129.

Biochemical and Cellular Characterization and Inhibitor Discovery of Pseudomonas aeruginosa 15-Lipoxygenase.

Deschamps JD, Ogunsola AF, Jameson JB, et al.

Biochemistry 2016; (55(23)):3329-40 doi:10.1021/acs.biochem.6b00338.

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Kalil AC, Metersky ML, Klompas M, et al.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016; (63(5)):e61-e111 doi:10.1093/cid/ciw353.

Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Kalil AC, Metersky ML, Klompas M, et al.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016; (63(5)):575-82 doi:10.1093/cid/ciw504.

Pseudomonas aeruginosa Type III Secretory Toxin ExoU and Its Predicted Homologs.

Sawa T, Hamaoka S, Kinoshita M, et al.

Toxins 2016; (8(11)).

Cooperative Substrate-Cofactor Interactions and Membrane Localization of the Bacterial Phospholipase A2 (PLA2) Enzyme, ExoU.

Tessmer MH, Anderson DM, Buchaklian A, et al.

The Journal of biological chemistry 2017; (292(8)):3411-3419 doi:10.1074/jbc.M116.760074.

Nosocomial Infections with IMP-19-Producing Pseudomonas aeruginosa Linked to Contaminated Sinks, France.

Amoureux L, Riedweg K, Chapuis A, et al.

Emerging infectious diseases 2017; (23(2)):304-307 doi:10.3201/eid2302.160649.

Engineering waterborne Pseudomonas aeruginosa out of a critical care unit.

Garvey MI, Bradley CW, Wilkinson MAC, et al.

International journal of hygiene and environmental health 2017; (220(6)):1014-1019 doi:10.1016/j.ijheh.2017.05.011.

Necrotizing Pseudomonas aeruginosa Community-Acquired Pneumonia: A Case Report and Review of the Literature.

Maharaj S, Isache C, Seegobin K, et al.

Case reports in infectious diseases 2017; (2017()):1717492 doi:10.1155/2017/1717492.

Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: Prevalence and risk factors.

Trinh TD, Zasowski EJ, Claeys KC, et al.

Diagnostic microbiology and infectious disease 2017; (89(1)):61-66 doi:10.1016/j.diagmicrobio.2017.06.009.

Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.

Grupper M, Sutherland C, Nicolau DP

Antimicrobial agents and chemotherapy 2017; (61(10)) doi:10.1128/AAC.00875-17.

The Diagnostic Yield of Noninvasive Microbiologic Sputum Sampling in a Cohort of Patients with Clinically Diagnosed Hospital-Acquired Pneumonia.

Naidus EL, Lasalvia MT, Marcantonio ER, Herzig SJ

Journal of hospital medicine 2018; (13(1)):34-37 doi:10.12788/jhm.2868.

Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.

Torres A, Zhong N, Pachl J, et al.

The Lancet. Infectious diseases 2018; (18(3)):285-295 doi:10.1016/S1473-3099(17)30747-8.

PvdQ Quorum Quenching Acylase Attenuates Pseudomonas aeruginosa Virulence in a Mouse Model of Pulmonary Infection.

Utari PD, Setroikromo R, Melgert BN, Quax WJ

Frontiers in cellular and infection microbiology 2018; (8()):119 doi:10.3389/fcimb.2018.00119.

Pseudomonas aeruginosa Quorum Sensing Systems as Drug Discovery Targets: Current Position and Future Perspectives.

Soukarieh F, Williams P, Stocks MJ, Cámara M

Journal of medicinal chemistry 2018; (61(23)):10385-10402 doi:10.1021/acs.jmedchem.8b00540.

An outbreak of multidrug-resistant Pseudomonas aeruginosa in a burns service in the North of England: challenges of infection prevention and control in a complex setting.

Decraene V, Ghebrehewet S, Dardamissis E, et al.

The Journal of hospital infection 2018; (100(4)):e239-e245 doi:10.1016/j.jhin.2018.07.012.

Impact of concomitant nontuberculous mycobacteria and Pseudomonas aeruginosa isolates in non-cystic fibrosis bronchiectasis.

Hsieh MH, Lin CY, Wang CY, et al.

Infection and drug resistance 2018; (11()):1137-1143 doi:10.2147/IDR.S169789.

Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia.

Khawcharoenporn T, Chuncharunee A, Maluangnon C, et al.

International journal of antimicrobial agents 2018; (52(6)):828-834 doi:10.1016/j.ijantimicag.2018.09.008.

Elimination of Australian epidemic strain (AES1) pseudomonas aeruginosa in a pediatric cystic fibrosis center.

Kevat A, Carzino R, Massie J, et al.

Pediatric pulmonology 2018; (53(11)):1498-1503 doi:10.1002/ppul.24173.

Pyrimidine Biosynthesis Regulates the Small-Colony Variant and Mucoidy in Pseudomonas aeruginosa through Sigma Factor Competition.

Al Ahmar R, Kirby BD, Yu HD

Journal of bacteriology 2019; (201(1)) doi:10.1128/JB.00575-18.

Pretreatment with cathelicidin-BF ameliorates Pseudomonas aeruginosa pneumonia in mice by enhancing NETosis and the autophagy of recruited neutrophils and macrophages.

Liu C, Qi J, Shan B, et al.

International immunopharmacology 2018; (65()):382-391 doi:10.1016/j.intimp.2018.10.030.

Targeting the Pseudomonas quinolone signal quorum sensing system for the discovery of novel anti-infective pathoblockers.

Schütz C, Empting M

Beilstein journal of organic chemistry 2018; (14()):2627-2645 doi:10.3762/bjoc.14.241.

Adaptation of Pseudomonas aeruginosa to the chronic phenotype by mutations in the algTmucABD operon in isolates from Brazilian cystic fibrosis patients.

Candido Caçador N, Paulino da Costa Capizzani C, Gomes Monteiro Marin Torres LA, et al.

PloS one 2018; (13(11)):e0208013 doi:10.1371/journal.pone.0208013.

Septic shock secondary to an acute necrotizing community-acquired pneumonia with bacteremia due to Pseudomonas aeruginosa.

Riviere P, Patin D, Delaporte E, et al.

IDCases 2019; (17()):e00563 doi:10.1016/j.idcr.2019.e00563.

Emerging strategies for the noninvasive diagnosis of nosocomial pneumonia.

Liapikou A, Cillóniz C, Torres A

Expert review of anti-infective therapy 2019; (17(7)):523-533 doi:10.1080/14787210.2019.1635010.

Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections.

Horcajada JP, Montero M, Oliver A, et al.

Clinical microbiology reviews 2019; (32(4)) doi:10.1128/CMR.00031-19.

Pseudomonas aeruginosa and microbial keratitis.

Hilliam Y, Kaye S, Winstanley C

Journal of medical microbiology 2020; (69(1)):3-13 doi:10.1099/jmm.0.001110.

Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections.

Giannella M, Bussini L, Pascale R, et al.

Open forum infectious diseases 2019; (6(12)):ofz505 doi:10.1093/ofid/ofz505.

Meta-Analysis of Biofilm Formation, Antibiotic Resistance Pattern, and Biofilm-Related Genes in Pseudomonas aeruginosa Isolated from Clinical Samples.

Karballaei Mirzahosseini H, Hadadi-Fishani M, Morshedi K, Khaledi A

Microbial drug resistance (Larchmont, N.Y.) 2020; (26(7)):815-824 doi:10.1089/mdr.2019.0274.

Experience With Ceftolozane-Tazobactam for the Treatment of Serious Pseudomonas aeruginosa Infections in Saudi Tertiary Care Center.

Bosaeed M, Ahmad A, Alali A, et al.

Infectious diseases 2020; (13()):1178633720905977 doi:10.1177/1178633720905977.

Biochemical and computational study of an alginate lyase produced by Pseudomonas aeruginosa strain S21.

Piroozmand F, Ghadam P, Zarrabi M, Abdi-Ali A

Iranian journal of basic medical sciences 2020; (23(4)):454-460 doi:10.22038/ijbms.2020.37277.8874.

Release mechanisms and molecular interactions of Pseudomonas aeruginosa extracellular DNA.

Sarkar S

Applied microbiology and biotechnology 2020; (104(15)):6549-6564 doi:10.1007/s00253-020-10687-9.

Overproduction of the AlgT Sigma Factor Is Lethal to Mucoid Pseudomonas aeruginosa.

Cross AR, Raghuram V, Wang Z, et al.

Journal of bacteriology 2020; (202(20)) doi:10.1128/JB.00445-20.

Airway Microbiology in Tracheostomized Children.

McLaren D, Chitakis M, Burns H, Kapur N

Respiratory care 2021; (66(2)):281-285 doi:10.4187/respcare.07890.

Hospital-acquired and ventilator-associated pneumonia: Diagnosis, management, and prevention.

Modi AR, Kovacs CS

Cleveland Clinic journal of medicine 2020; (87(10)):633-639 doi:10.3949/ccjm.87a.19117.

Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).

Tamma PD, Aitken SL, Bonomo RA, et al.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021; (72(7)):e169-e183 doi:10.1093/cid/ciaa1478.

Draft Genome Sequence of Pseudomonas aeruginosa Strain PA14-UM.

Lee VT, Ghodssi R, El-Sayed NM, et al.

Microbiology resource announcements 2020; (9(46)) doi:10.1128/MRA.00978-20.

Pseudomonas aeruginosa Biofilms.

Thi MTT, Wibowo D, Rehm BHA

International journal of molecular sciences 2020; (21(22)) doi:10.3390/ijms21228671.

Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases.

Garcia-Clemente M, de la Rosa D, Máiz L, et al.

Journal of clinical medicine 2020; (9(12)) doi:10.3390/jcm9123800.

Meta-analysis of efficacy and safety of inhaled ciprofloxacin in non-cystic fibrosis bronchiectasis patients.

Wang S, Zhang A, Yao X

Internal medicine journal 2021; (51(9)):1505-1512 doi:10.1111/imj.15210.

Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019.

Karlowsky JA, Lob SH, Young K, et al.

BMC microbiology 2021; (21(1)):74 doi:10.1186/s12866-021-02135-z.

Pathogenesis of Gram-Negative Bacteremia.

Holmes CL, Anderson MT, Mobley HLT, Bachman MA

Clinical microbiology reviews 2021; (34(2)) doi:10.1128/CMR.00234-20.

Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).

Tamma PD, Aitken SL, Bonomo RA, et al.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021; (72(7)):1109-1116 doi:10.1093/cid/ciab295.

Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications.

Kwok WC, Ho JCM, Tam TCC, et al.

Respiratory research 2021; (22(1)):132 doi:10.1186/s12931-021-01729-5.

The Impact of Quarantine on Sleep Quality and Psychological Distress During the COVID-19 Pandemic.

AlRasheed MM, Alkadir AM, Bin Shuqiran KI, et al.

Nature and science of sleep 2021; (13()):1037-1048 doi:10.2147/NSS.S313373.

The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update.

Reynolds D, Kollef M

Drugs 2021; (81(18)):2117-2131 doi:10.1007/s40265-021-01635-6.

The Role of Pseudomonas aeruginosa Virulence Factors in Cytoskeletal Dysregulation and Lung Barrier Dysfunction.

Wagener BM, Hu R, Wu S, et al.

Toxins 2021; (13(11)) doi:10.3390/toxins13110776.

Repurposing Sitafloxacin, Prulifloxacin, Tosufloxacin, and Sisomicin as Antimicrobials Against Biofilm and Persister Cells of Pseudomonas aeruginosa.

She P, Li S, Liu Y, et al.

Current microbiology 2021; (79(1)):12 doi:10.1007/s00284-021-02729-w.

Loneliness and psychological distress before and during the COVID-19 pandemic: Relationships with social media identity bubbles.

Latikka R, Koivula A, Oksa R, et al.

Social science & medicine (1982) 2022; (293()):114674 doi:10.1016/j.socscimed.2021.114674.

Community-acquired Pseudomonas aeruginosa pneumonia manifested by bloody pleural effusion in a previously healthy infant: A case report.

Dong C, Shen F, Dong H, et al.

Journal of clinical laboratory analysis 2022; (36(6)):e24466 doi:10.1002/jcla.24466.

Risk factor-based analysis of community-acquired pneumonia, healthcare-associated pneumonia and hospital-acquired pneumonia: Microbiological distribution, antibiotic resistance, and clinical outcomes.

Hyun H, Song JY, Yoon JG, et al.

PloS one 2022; (17(6)):e0270261 doi:10.1371/journal.pone.0270261.

Microbiologic pattern and clinical outcome of non-ICU-acquired pneumonia: Korean HAP registry analysis.

Jang JH, Yeo HJ, Kim T, et al.

The Korean journal of internal medicine 2022; (37(4)):800-810 doi:10.3904/kjim.2021.348.

Clinical risk factors for admission with Pseudomonas and multidrug-resistant Pseudomonas community-acquired pneumonia.

Idigo AJ, Wells JM, Brown ML, et al.

Antimicrobial resistance and infection control 2022; (11(1)):95 doi:10.1186/s13756-022-01137-4.

Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients.

Giamarellou H, Karaiskos I

Antibiotics (Basel, Switzerland) 2022; (11(8)) doi:10.3390/antibiotics11081009.

Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.

Weber C, Schultze T, Göttig S, et al.

Microbiology spectrum 2022; (10(5)):e0169722 doi:10.1128/spectrum.01697-22.

Pseudomonas aeruginosa Antivirulence Strategies: Targeting the Type III Secretion System.

Goldberg JB, Crisan CV, Luu JM

Advances in experimental medicine and biology 2022; (1386()):257-280 doi:10.1007/978-3-031-08491-1_9.

Pro-resolving and pro-inflammatory fatty acid-derived mediators in sputum of stable state bronchiectasis patients.

Terranova L, Risé P, Gramegna A, et al.

Respiratory research 2022; (23(1)):363 doi:10.1186/s12931-022-02301-5.

New antibiotics for Gram-negative pneumonia.

Bassetti M, Magnè F, Giacobbe DR, et al.

European respiratory review : an official journal of the European Respiratory Society 2022; (31(166)) doi:10.1183/16000617.0119-2022.

Pseudomonas aeruginosa virulence attenuation by inhibiting siderophore functions.

Jeong GJ, Khan F, Khan S, et al.

Applied microbiology and biotechnology 2023; (107(4)):1019-1038 doi:10.1007/s00253-022-12347-6.

In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018-20.

Karlowsky JA, Lob SH, Akrich B, et al.

JAC-antimicrobial resistance 2023; (5(1)):dlad003 doi:10.1093/jacamr/dlad003.

Decreased Sphingosine Due to Down-Regulation of Acid Ceramidase Expression in Airway of Bronchiectasis Patients: A Potential Contributor to Pseudomonas aeruginosa Infection.

Qi Q, Xu J, Wang Y, et al.

Infection and drug resistance 2023; (16()):2573-2588 doi:10.2147/IDR.S407335.

A Fatal Case of Pseudomonas aeruginosa Community-Acquired Pneumonia in an Immunocompetent Patient: Clinical and Molecular Characterization and Literature Review.

Barp N, Marcacci M, Biagioni E, et al.

Microorganisms 2023; (11(5)) doi:10.3390/microorganisms11051112.

Detection and imaging of bacterial biofilms with glutathione-stabilized gold nanoclusters.

Evstigneeva SS, Chumakov DS, Tumskiy RS, et al.

Talanta 2023; (264()):124773 doi:10.1016/j.talanta.2023.124773.

A Deep Learning Model for the Diagnosis and Discrimination of Gram-Positive and Gram-Negative Bacterial Pneumonia for Children Using Chest Radiography Images and Clinical Information.

Wen R, Xu P, Cai Y, et al.

Infection and drug resistance 2023; (16()):4083-4092 doi:10.2147/IDR.S404786.

Microbiological patterns of bacterial infections in tracheostomized children: Reducing uncertainty in continuous care.

García-Boyano M, Alcalá FJC, Alonso AR, et al.

Pediatric pulmonology 2023; (58(12)):3507-3515 doi:10.1002/ppul.26684.

A score to predict Pseudomonas aeruginosa infection in older patients with community-acquired pneumonia.

Wijit K, Sonthisombat P, Diewsurin J

BMC infectious diseases 2023; (23(1)):700 doi:10.1186/s12879-023-08688-w.

MDR/XDR/PDR or DTR? Which definition best fits the resistance profile of Pseudomonas aeruginosa?

Cosentino F, Viale P, Giannella M

Current opinion in infectious diseases 2023; (36(6)):564-571 doi:10.1097/QCO.0000000000000966.

Emergence of cefiderocol resistance during ceftazidime/avibactam treatment caused by a large genomic deletion, including ampD and piuCD genes, in Pseudomonas aeruginosa.

Gomis-Font MA, Clari MA, López-Causapé C, et al.

Antimicrobial agents and chemotherapy 2024; (68(1)):e0119223 doi:10.1128/aac.01192-23.

Quercetin: a promising virulence inhibitor of Pseudomonas aeruginosa LasB in vitro.

Ren Y, Zhu R, You X, et al.

Applied microbiology and biotechnology 2024; (108(1)):57 doi:10.1007/s00253-023-12890-w.

Impact of Multiplex PCR in the Therapeutic Management of Severe Bacterial Pneumonia.

Dessajan J, Timsit JF

Antibiotics (Basel, Switzerland) 2024; (13(1)) doi:10.3390/antibiotics13010095.

Effectiveness of novel β-lactams for Pseudomonas aeruginosa infection: A systematic review and meta-analysis.

Huang M, Cai F, Liu C, et al.

American journal of infection control 2024; (52(7)):774-784 doi:10.1016/j.ajic.2024.02.016.

Antibacterial peptide Reg4 ameliorates Pseudomonas aeruginosa-induced pulmonary inflammation and fibrosis.

Wan X, Wang W, Zhu J, Xiao Y

Microbiology spectrum 2024; (12(5)):e0390523 doi:10.1128/spectrum.03905-23.

Hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative pathogens: Understanding epidemiology, resistance patterns, and implications with COVID-19.

Hammoudi Halat D, Ayoub Moubareck C

F1000Research 2023; (12()):92 doi:10.12688/f1000research.129080.2.

Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.

Buyukyanbolu E, Genc L, Cyr EA, et al.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2024; (43(9)):1787-1794 doi:10.1007/s10096-024-04896-7.

The psychological impact of diagnosis of sinonasal, nasopharyngeal, and laryngeal cancers: a systematic review.

Bonafede M, d'Errico A, Rugarli S, et al.

Frontiers in psychology 2024; (15()):1355186 doi:10.3389/fpsyg.2024.1355186.

The Uncommon Suspect: Pseudomonas aeruginosa and Cavitary Lung Lesions in an Immunocompetent Patient.

Allena N, Arshad M, Athar ZM, et al.

Cureus 2024; (16(8)):e66075 doi:10.7759/cureus.66075.

Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months.

Haworth CS, Shteinberg M, Winthrop K, et al.

The Lancet. Respiratory medicine 2024; (12(10)):787-798 doi:10.1016/S2213-2600(24)00225-X.

Associations between respiratory pathogens and lung function in primary ciliary dyskinesia: cross-sectional analysis from the PROVALF-PCD cohort.

Rubbo B, Kant A, Zhang K, et al.

ERJ open research 2024; (10(5)) doi:10.1183/23120541.00253-2024.

Characteristics of different pathogenic bacterial infections and their effects on prognosis in adult patients with bronchiectasis.

Niu Y, Lian X, Li X, et al.

Experimental and therapeutic medicine 2024; (28(6)):455 doi:10.3892/etm.2024.12745.

Difference of Clinical Manifestation Between Infection and Colonization of Pseudomonas aeruginosa Among Patients With Community-Acquired Pneumonia.

Hirota S, Goto A, Shuto H, Komiya K

Cureus 2024; (16(11)):e73298 doi:10.7759/cureus.73298.

Effect of empiric antibiotics against Pseudomonas aeruginosa on mortality in hospitalized patients: a systematic review and meta-analysis.

Hunter CJ, Marhoffer EA, Holleck JL, et al.

The Journal of antimicrobial chemotherapy 2025; (80(2)):322-333 doi:10.1093/jac/dkae422.

Vicarious trauma, coping strategies and nurses' health outcomes: An exploratory study.

Piras I, Usai V, Contu P, Galletta M

AIMS public health 2024; (11(4)):1071-1081 doi:10.3934/publichealth.2024055.

Clinical Implications of Pseudomonas Aeruginosa Colonization in Chronic Obstructive Pulmonary Disease Patients.

Kwok WC, Tam TCC, Chau CH, et al.

Chronic obstructive pulmonary diseases (Miami, Fla.) 2025; (12(2)):137-145 doi:10.15326/jcopdf.2024.0582.

Different aspects of Pseudomonas aeruginosa biofilm: an in-depth analysis from formation to detection.

Rawat N, Sheoran S, Khan J, et al.

Naunyn-Schmiedeberg's archives of pharmacology 2025; (398(8)):9529-9549 doi:10.1007/s00210-025-03971-w.

Non-Cystic Fibrosis Bronchiectasis in Adults: A Review.

Barker AF, Karamooz E

JAMA 2025; (334(3)):253-264 doi:10.1001/jama.2025.2680.

Pseudomonas aeruginosa biofilm: treatment strategies to combat infection.

Ramesh R, Rekha ND, Gopal S

Archives of microbiology 2025; (207(6)):141 doi:10.1007/s00203-025-04346-8.

Difficult-to-treat resistant Pseudomonas aeruginosa infections in Lebanese hospitals: Impact on mortality and the role of initial antibiotic therapy.

Itani R, Khojah HMJ, Mukattash TL, et al.

PloS one 2025; (20(5)):e0321935 doi:10.1371/journal.pone.0321935.

Weighing options: empiric antibiotic use and stewardship opportunities in critically ill patients with community-acquired pneumonia.

Trujillo N, Diep C, Ha D, et al.

Antimicrobial stewardship & healthcare epidemiology : ASHE 2025; (5(1)):e180 doi:10.1017/ash.2025.10082.

Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020-2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program.

Kimbrough JH, Karr MH, Nguyen ST, et al.

Microbiology spectrum 2025; (13(11)):e0207925 doi:10.1128/spectrum.02079-25.

First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa.

Dorazio AJ, Aitken SL, Pierce VM, et al.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026; (82(1)):44-48 doi:10.1093/cid/ciaf638.

Predictors of Mortality in Pseudomonas aeruginosa Bloodstream Infections: A Scoping Review.

Abdul Jabar K, Romli NIA, Vellasamy KM, et al.

Pathogens (Basel, Switzerland) 2026; (15(1)) doi:10.3390/pathogens15010061.

Seven-year surveillance of antimicrobial resistance in respiratory pathogens at a Ugandan referral hospital: Emerging trends and stewardship priorities.

Bazira J, Nakimuli CN, Nalumaga PP, et al.

African journal of thoracic and critical care medicine 2025; (31(4)):e3495 doi:10.7196/AJTCCM.2025.v31i4.3495.

Tau is necessary for Pseudomonas aeruginosa-induced blood-brain barrier dysfunction.

Chaney SD, Bauman AJ, Butlig ER, et al.

Communications biology 2026; (9(1)).